Rodolphe Barrangou

This inventor holds 37 USPTO granted patents and 18 published patent applications, plus 3 CIPO patents and 14 EPO patents, primarily in Genome Engineering. Top assignees: North Carolina State University, Dupont Nutrition Biosciences Aps, Lifeedit Therapeutics, Inc.. Active years: 2008-2026. National Inventors Hall of Fame inductee.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rodolphe Barrangou. Retrieved from https://idiyas.com/inventor/rodolphe-barrangou

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 18)

% Patents Active = 73.0

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 14 (Patent Applications = 31)

Average Co-Inventor Count = 3.1

ph-index = 8

Forward Citations = 500(Granted Patents)

Location History:

Madison, WI (US) (2008 - 2020)
Raleigh, NC (US) (2018 - 2024)

Company Filing History:

22 out of 1,489

North Carolina State University

patents

10 out of 149

Dupont Nutrition Biosciences Aps

patents

4 out of 18

Lifeedit Therapeutics, Inc.

where one patent can have more than one assignee

Years Active: 2008-2026

Loading Chart...

Areas of Expertise:

CRISPR-Cas Systems

Genome Modification

RNA-Guided Nucleases

Cas9 Proteins

Antimicrobial Delivery

Bacterial Screening

Eukaryotes

Cell Resistance

Lactic Acid Bacteria

Bifidobacteria

Phage Resistance

Fructo-Oligosaccharides

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12698490 - Methods and compositions for sequences guiding Cas9 targeting (2026-08-04),

2. 12655437 - COMPOSITIONS AND METHODS FOR MODULATING THE GASTROINTESTINAL TRACT USING BILE SALT HYDROLASES (2026-06-16),

3. 12655426 - Polypeptides useful for gene editing and methods of use (2026-06-16),

4. 12509492 - GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYOTES (2025-12-30),

5. 12338455 - RNA-guided nucleases and active fragments and variants thereof and methods of use (2025-06-24),

6. 12264330 - Recombinant type I CRISPR-Cas system and uses thereof for killing target cells (2025-04-01),

7. 12264313 - Recombinant type I CRISPR-Cas system and uses thereof for genome modification and alteration of expression (2025-04-01),

8. 12203123 - Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells (2025-01-21),

9. 11926843 - RNA-guided nucleases and active fragments and variants thereof and methods of use (2024-03-12),

10. 11753651 - Cas9 proteins and guiding features for DNA targeting and genome editing (2023-09-12),

11. 11680259 - Recombinant type I CRISPR-CAS system (2023-06-20),

12. 11542466 - Methods and compositions for delivery of CRISPR based antimicrobials (2023-01-03),

13. 11499169 - Compositions and methods related to a type-II CRISPR-Cas system in (2022-11-15),

14. 11261451 - Methods for screening bacteria, archaea, algae, and yeast using CRISPR nucleic acids (2022-03-01),

15. 11162114 - RNA-guided nucleases and active fragments and variants thereof and methods of use (2021-11-02),

Title: The Innovator Shaping the Future: Rodolphe Barrangou

Introduction: Rodolphe Barrangou, a distinguished inventor based in Raleigh, NC, with a remarkable portfolio of 29 patents, is revolutionizing the field of molecular biology with his groundbreaking work in RNA-guided nucleases and genome editing technologies.

Latest Patents: Barrangou's latest patents include pioneering inventions such as RNA-guided nucleases and active fragments for precise genetic modifications, as well as novel CRISPR systems for genome editing and transcriptional control. These inventions have the potential to transform various industries by enabling targeted gene editing and manipulation.

Career Highlights: Throughout his illustrious career, Rodolphe Barrangou has collaborated with renowned institutions and companies. He has made significant contributions during his tenure at North Carolina State University and Dupont Nutrition Biosciences Aps, where his innovative research has paved the way for advancements in molecular biology and genetic engineering.

Collaborations: Barrangou has worked closely with esteemed colleagues such as Philippe Horvath and Dennis A. Romero, pooling their expertise to push the boundaries of science and technology. These collaborations have resulted in impactful developments in the field of CRISPR technologies and genetic engineering.

Conclusion: Rodolphe Barrangou's dedication to innovation and his relentless pursuit of scientific advancement continue to inspire and drive progress in the realms of molecular biology and genetic engineering. His groundbreaking inventions and collaborative efforts underscore his status as a visionary inventor shaping the future of biotechnology.

Profile summary based on public USPTO records.